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Abstract
Introduction The mechanism of coagulation activation during
continuous venovenous hemofiltration (CVVH) has not yet been
elucidated. Insight into the mechanism(s) of hemostatic
activation within the extracorporeal circuit could result in a more
rational approach to anticoagulation. The aim of the present
study was to investigate whether CVVH using cellulose
triacetate filters causes activation of the contact factor pathway
or of the tissue factor pathway of coagulation. In contrast to
previous studies, CVVH was performed without anticoagulation.
Methods Ten critically ill patients were studied prior to the start
of CVVH and at 5, 15 and 30 minutes and 1, 2, 3 and 6 hours
thereafter, for measurement of prothrombin fragment F1+2,
soluble tissue factor, activated factor VII, tissue factor pathway
inhibitor, kallikrein–C1-inhibitor and activated factor XII–C1-
inhibitor complexes, tissue-type plasminogen activator,
plasminogen activator inhibitor type I, plasmin–antiplasmin
complexes, protein C and antithrombin.
Results During the study period the prothrombin fragment
F1+2 levels increased significantly in four patients (defined as
group A) and did not change in six patients (defined as group B).
Group A also showed a rapid increase in transmembrane
pressure, indicating clotting within the filter. At baseline, the
activated partial thromboplastin time, the prothrombin time and
the kallikrein–C1-inhibitor complex and activated factor XII–C1-
inhibitor complex levels were significantly higher in group B,
whereas the platelet count was significantly lower in group B.
For the other studied markers the differences between group A
and group B at baseline were not statistically significant. During
CVVH the difference in the time course between group A and
group B was not statistically significant for the markers of the
tissue factor system (soluble tissue factor, activated factor VII
and tissue factor pathway inhibitor), for the markers of the
contact system (kallikrein–C1-inhibitor and activated factor XII–
C1-inhibitor complexes) and for the markers of the fibrinolytic
system (plasmin–antiplasmin complexes, tissue-type
plasminogen activator and plasminogen activator inhibitor type
I).
Conclusion Early thrombin generation was detected in a
minority of intensive care patients receiving CVVH without
anticoagulation. Systemic concentrations of markers of the
tissue factor system and of the contact system did not change
during CVVH. To elucidate the mechanism of clot formation
during CVVH we suggest that future studies are needed that
investigate the activation of coagulation directly at the site of the
filter. Early coagulation during CVVH may be related to lower
baseline levels of markers of contact activation.
CRRT = continuous renal replacement therapy; CVVH = continuous venovenous hemofiltration; ELISA = enzyme-linked immunosorbent assay; F1+2 
= prothrombin fragment F1+2; FVIIa = activated factor VII; FXIIa = activated factor XII; IL = interleukin; PAP = plasmin–antiplasmin; TFPI = tissue 
factor pathway inhibitor; t-PA = tissue type plasminogen activator.Critical Care    Vol 10 No 5    Bouman et al.
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Introduction
Acute renal failure requiring renal replacement therapy occurs
in approximately 4% of patients admitted to the intensive care
unit, and often these patients are treated with some form of
continuous renal replacement therapy (CRRT) [1]. CRRT
requires anticoagulation to allow the passage of blood through
the extracorporeal circuit over a prolonged period. Mainte-
nance of CRRT circuits for sufficient duration is important for
efficacy, cost-effectiveness and minimization of blood compo-
nent loss. On the other hand, the systemic anticoagulation
techniques used to prevent clotting of the circuit are important
causes of morbidity in CRRT. Understanding the mechanisms
involved in premature clotting of the filtration circuit is manda-
tory to optimize anticoagulation and to maintain filter patency.
Several studies have addressed the pathophysiology of circuit
thrombogenesis, but the exact mechanism by which it occurs
has not yet been elucidated. Multiple factors may play a role:
the extracorporeal circuit itself, treatment modalities, platelet
factors, coagulation factors, natural anticoagulants and fibri-
nolysis [2,3]. Clotting of CRRT circuits could be caused by
increased activation of coagulation, initiated either by the
(intrinsic) contact activation pathway or the (extrinsic) tissue
factor/activated factor VII (FVIIa) pathway, or by low activity of
the endogenous anticoagulant pathways, such as the anti-
thrombin system, the protein C/protein S system and the tis-
sue factor pathway inhibitor system. In addition, decreased
fibrinolysis could also contribute to clotting of extracorporeal
circuits.
Although much is known about the effect of a single hemodi-
alysis treatment on the coagulation system, very few prospec-
tive studies have monitored the effects of repeated passage of
blood through a CRRT circuit, and these studies were always
performed with concurrent administration of anticoagulants,
usually unfractionated heparin or low molecular weight heparin
[4-7]. As heparin influences tissue-factor-mediated coagula-
tion, contact-activated coagulation [7] and fibrinolysis [8],
however, studies on the activation of coagulation during CRRT
should ideally be performed without anticoagulation.
In the present study in critically ill patients with acute renal fail-
ure, we studied the effects of continuous venovenous hemofil-
tration (CVVH) without the use of anticoagulation on the
activation of coagulation and fibrinolysis.
Materials and methods
Patients
The study was approved by the institutional review board and
written informed consent was obtained from all participants or
their authorized representatives. A cohort of 10 critically ill
patients with acute renal failure requiring CVVH was studied.
Patients were excluded if they fulfilled one of the following cri-
teria: treatment with coumarins or platelet aggregation inhibi-
tors within one week prior to starting CVVH; unfractionated
heparin within 12 hours prior to starting CVVH or low molecu-
lar weight heparin within 48 hours prior to starting CVVH;
treatment with extracorporeal techniques within 48 hours prior
to starting CVVH; or discontinuation of CVVH for any reason
other than clotting of the circuit (for example, transfer for a
computed tomography scan).
Continuous venovenous hemofiltration
Vascular access was obtained by insertion of a 14 F double-
lumen catheter (Duo-Flow 400 XL; Medcomp, Harleysville,
PA, USA) into a large vein (femoral, subclavian or internal jug-
ular vein). Hemofiltration was performed with computer-con-
trolled, fully automated hemofiltration machines (Diapact;
Braun AG, Melsungen, Germany). A 1.9 m2 cellulose triace-
tate hollow-fiber membrane with a sieving coefficient for β2-
microglobulin of approximately 0.82 was used (CT190G; Bax-
ter, McGaw Park, IL, USA). The blood flow rate was 150 ml/
minute and warmed substitution fluid was added in predilution
mode at a flow rate of 2 l/hour. The hemofiltration run contin-
ued until the extracorporeal circuit clotted. No anticoagulant
was used during CVVH, and neither was the extracorporeal
circuit primed with any anticoagulant.
Blood collection
Blood was drawn from the venous limb of the hemofiltration
catheter before starting hemofiltration, and at 5, 15 and 30
minutes and at 1, 2, 3 and 6 hours after commencement of
CVVH. For the determination of contact activation 4.8 ml
blood was collected in siliconized vacutainer tubes, to which
0.2 ml of a mixture of ethylenediamine tetraacetic acid (0.25
M), benzamidine (0.25 M) and soybean–trypsin inhibitor
(0.25%) was added to prevent in vitro contact activation and
clotting. All other blood samples were collected in citrated
vacutainer tubes. Plasma was prepared by centrifugation of
blood twice at 2500 × g for 20 minutes at 16°C, followed by
storage at -80°C until assays were performed.
Assays
The plasma concentrations of prothrombin fragment F1+2
(F1+2) were measured by ELISA (Dade Behring, Marburg,
Germany). Soluble tissue factor was also determined by
ELISA (American Diagnostica, Greenwich, CT, USA). The
plasma concentration of FVIIa was determined on a Behring
Coagulation System (Dade Behring) with the StaClot VIIa-rTF
method from Diagnostica Stago (Asnières-sur-Seine, France).
The tissue factor pathway inhibitor (TFPI) activity was meas-
ured on the Behring Coagulation System (Dade Behring) as
described by Sandset and colleagues [9]. Kallikrein–C1-inhib-
itor and activated factor XII (FXIIa)–C1-inhibitor complexes
were measured as described by Nuijens and colleagues [10].
Tissue-type plasminogen activator (t-PA) antigen and plas-
minogen activator inhibitor type I antigen were assayed by
ELISA (Innotest PAI-1; Hyphen BioMed, Andrésy, France).
Antithrombin activity was determined with Berichrom Anti-
thrombin (Dade Behring) on a Behring Coagulation SystemAvailable online http://ccforum.com/content/10/5/R150
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(Dade Behring). Plasmin–antiplasmin (PAP) complexes were
determined with a PAP micro ELISA kit (DRG, Berlin, Ger-
many). Protein C was determined using the Coamatic protein
C activity kit from Chromogenix (Mölndal, Sweden).
Statistical analysis
Values are presented as the median (range). We used the
Mann-Whitney U test to analyze the difference between base-
line variables, and we used linear mixed models to evaluate the
difference over time between groups. Data were analyzed
using the Statistical Package for the Social Sciences for Win-
dows (version 11.0; SPSS, Chicago IL, USA). P < 0.05 was
considered significant. Hemofilter survival times were com-
pared using the Kaplan–Meier method and the log-rank test
(GraphPad Prism 4.0; GraphPad software Inc., San Diego
CA, USA).
Results
Baseline characteristics
The baseline characteristics of the 10 enrolled patients are
presented in Table 1.
Thrombin generation and clotting of the circuit
Nine out of 10 patients showed coagulation activation before
the initiation of CVVH, as reflected by increased F1+2 levels.
Figure 1 shows the F1+2 levels during CVVH for each patient.
The concentrations of F1+2 increased in patients 1, 2, 8 and
9 (defined as group A) and did not change in the other patients
(defined as group B) (P < 0.001). One hour after the onset of
CVVH, the relative increase in the transmembrane pressure
was significantly higher (P = 0.01) in group A compared with
group B (57% (42–80%) in group A and 2% (2–7%) in group
B). In group A the lifespan of the circuit was less than 4.3
hours in three patients, but one patient had an unexpected
long circuit run of 22.5 hours. The difference in circuit life span
was not significantly different between the two groups (Figure
2).
Baseline coagulation parameters
Coagulation parameters before the initiation of CVVH are pre-
sented in Table 2, along with their reference values. By com-
parison with group B, baseline levels of the activated partial
thromboplastin time, the kallikrein–C1-inhibitor complex and
the FXIIa–C1-inhibitor complex were significantly lower in
group A, whereas the platelet count was significantly higher in
group A.
Coagulation parameters during CVVH
The time courses of the coagulation markers are shown in Fig-
ures 2, 3, 4. Data points are shown as a percentage of the ini-
tial concentration for those markers that were not significantly
different at baseline (Figures 3 and 5), whereas data points are
shown as absolute values for those markers that were signifi-
cantly different at baseline (Figure 4). Analysis of the differ-
ence in the time course between group A and group B was
Table 1
Patient characteristics
Patient 
number
Age 
(years)
Gender Diagnosis APACHE II 
scorea
Cause of 
acute renal 
failure
Type of 
acute renal 
failure
Ureab 
(mmol/l)
Creatinineb 
(μmol/l)
Duration of 
the CVVH 
circuit studied 
(hours)
Filter 
lifespan 
(hours)
Outcome
Group A
1 44 Male Subarachnoidal 
hemorrhage
29 Nonseptic Anuric 21.8 432 3 4.3 Died
2 52 Male Lung cancer and 
pneumonia
10 Septic Oliguric 35 148 1 1.0 Died
8 68 Female Thoracic aortic 
prosthesis
15 Nonseptic Nonoliguri
c
37 415 6 22.5 Survived
9 64 Male Ruptured abdominal 
aortic aneurysm
14 Nonseptic Nonoliguri
c
46 379 1 1.5 Survived
Group B
3 65 Male Ruptured abdominal 
aortic aneurysm
28 Nonseptic Anuric 14.2 210 6 10.5 Survived
4 48 Male Streptococcal sepsis 23 Septic Oliguric 19.3 367 6 7.7 Survived
5 75 Male Myocardial infarction 23 Nonseptic Anuric 11.1 259 6 11.7 Died
6 65 Male Bowel ischemia 18 Septic Oliguric 33.8 368 6 7.0 Died
7 67 Male Non-Hodgkin lymphoma 24 Nonseptic Nonoliguri
c
44.8 392 6 31.0 Died
10 75 Male Peritonitis 23 Septic Oliguric 23.9 177 3 4.8 Died
Group A, patients with increased thrombin generation; group B, patients without increased thrombin generation. aAPACHE II score, acute 
physiology and chronic health evaluation II score at intensive care unit admission [26]. bBefore continuous venovenous hemofiltration (CVVH).Critical Care    Vol 10 No 5    Bouman et al.
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limited to the first three hours after the start of CVVH, because
only one patient in group A was still on CVVH at six hours.
The difference in the time course between groups A and B
was not significant for the tissue factor system (Figure 3) and
for the contact system (Figure 4). Levels of t-PA and plasmino-
gen activator inhibitor type 1 were also not significantly differ-
ent between group A and group B during CVVH (Figure 5).
The PAP complex levels tended to increase in group A during
CVVH (P = 0.07).
Discussion
In the present study in critically ill patients, we investigated the
early effects of CVVH without anticoagulation on systemic
markers of coagulation activation and fibrinolysis. During the
first six hours of CVVH, increased thrombin generation was
found in only four out of ten patients. An early increase in trans-
membrane pressure, indicating filter clotting, was exclusively
seen in the four patients with thrombin generation. Premature
clotting of the circuit was found in three of these four patients,
necessitating replacement of the circuit. CVVH without antico-
agulation did not change the systemic concentrations of mark-
ers of the intrinsic pathway or the extrinsic pathway, nor did
CVVH affect the systemic concentrations of fibrinolysis mark-
ers.
Thrombin generation on an artificial surface, such as the filter
membrane, has traditionally been attributed to contact activa-
tion of the intrinsic pathway of coagulation that starts upon
exposure of contact factors (factor XII, high molecular weight
kallikrein and prekallikrein) to a negatively charged surface and
their subsequent activation. We did not find any change in
plasma levels of the FXIIa–C1-inhibitor complex and the kal-
likrein-C1-inhibitor complex, making initiation of coagulation
via this pathway less likely. This finding confirms the results of
Salmon and colleagues, who did not find an increase in con-
tact activation during CVVH using a polyacrilonitrile mem-
brane and systemic heparinization [6]. Interestingly, in our
study baseline levels of the FXIIa–C1-inhibitor complex and
the kallikrein–C1-inhibitor complex were relatively lower in
patients with early increased thrombin generation during
CVVH. Several authors have described the role of FXIIa and
kallikrein in the activation of fibrinolysis [11,12]. Factor XII is
able to activate fibrinolysis by three different pathways: it acti-
vates prekallikrein, which in turn activates urokinase-type plas-
minogen activator; following the activation of prekallikrein, the
kallikrein generated can liberate t-PA; and factor XII activates
plasminogen directly.
Figure 1
Prothrombin fragment F1+2 during hemofiltration Prothrombin fragment F1+2 during hemofiltration. Curves represent values of individual patients. Group A, patients demonstrating an increase in 
thrombin generation. Group B, patients with a constant level of thrombin generation. F1+2, prothrombin fragment F1+2.
Figure 2
Kaplan–Meier survival function indicating hemofilter survival times Kaplan–Meier survival function indicating hemofilter survival times. Sur-
vival function indicating hemofilter survival times between patients with 
increased thrombin (group A, closed circles) and patients without 
increased thrombin generation (group B, open circles).Available online http://ccforum.com/content/10/5/R150
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The role of contact activation-dependent fibrinolysis in vivo is
unclear, but a relationship between contact activation-
dependent fibrinolysis and thromboembolic complications has
been described [13,14]. Low baseline activation of the con-
tact system may therefore be associated with lower fibrinolysis
and an increased risk of filter clotting. In our study, however,
fibrinolysis during CVVH was not decreased in group A. On
the contrary, we observed a trend towards increased PAP lev-
els during CVVH in patients with early clotting of the filter. This
PAP level increase is most probably caused by activated
coagulation leading to plasmin generation from plasminogen
on the formed fibrin. In this respect, therefore, the PAP levels
may be more an indication of coagulation than of fibrinolytic
activity itself.
Table 2
Baseline levels of coagulation markers
Coagulation marker Group A Group B P value Normal range (reference value)
Prothrombin fragment F1+2 (nmol/l) 2.5 (0.9–3.8) 4.1 (2.3–6.6) 0.20 0.3–1.6
Soluble tissue factor (pg/ml) 126 (73–216) 207 (30–322) 0.59 55–256
Activated factor VII (mU/ml) 61 (14–141) 97 (20–267) 0.52 16–142
Tissue factor pathway inhibitor (ng/ml) 167 (104–192) 127 (56–200) 0.83 39–149
Antithrombin (%) 78 (46–100) 45 (16–81) 0.09 80–140
Protein C (%) 63 (29–164) 41 (16–89) 0.34 65–110
Plasmin–antiplasmin complexes (ng/ml) 682 (635–788) 727 (281–1287) 1.0 221–512
Tissue-type plasminogen activator (ng/ml) 14.3 (7.0–44.6) 11.7 (8.6–51.7) 0.75 1.5–15
Plasminogen activator inhibitor type 1 (ng/ml) 135 (16–275) 526 (129–2191) 0.06 10–70
Kallikrein–C1-inhibitor complex (mU/ml) 8.2 (5.1–9.9) 11.1 (8.5–18.5) 0.02 <0.6
Activated factor XII–C1-inhibitor complex (mU/ml) 1.6 (1.3–1.8) 2.4 (1.8–4.4) 0.02 <0.5
Platelet count (× 109/l) 136 (90–329) 63 (30–101) 0.02 150–350
Prothrombin time (s) 13.5 (12.7–16.9) 17.5 (15.2–26.1) 0.05 10–13
Activated partial thromboplastin time (s) 25 (21–29) 37 (27–57) 0.02 21–27
Group A, patients with increased thrombin generation; group B, patients without increased thrombin generation. Data presented as median 
(range).
Figure 3
Soluble tissue factor, activated factor VII and tissue factor pathway inhibitor during hemofiltration Soluble tissue factor, activated factor VII and tissue factor pathway inhibitor during hemofiltration. Data points are median and interquartile ranges. 
Closed circles, patients with thrombin generation (group A); open circles, patients without thrombin generation (group B). P value represents the dif-
ference in time course between both groups by linear mixed models and during the first three hours of hemofiltration. sTF, soluble tissue factor; fac-
tor VIIa, activated factor VII; TFPI, tissue factor pathway inhibitor.Critical Care    Vol 10 No 5    Bouman et al.
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Alternatively, one could speculate that patients with higher
baseline levels of FXIIa–C1-inhibitor complex and kallikrein–
C1-inhibitor complex have higher baseline thrombin genera-
tion. Baseline F1+2 levels were higher in group B than in
group A, although the difference was not statistically signifi-
cant, possibly due to the small number of patients. Thrombin is
required for activation of the endogenous anticoagulant pro-
tein C system [15,16]. In patients with higher levels of FXIIa–
C1-inhibitor complex and kallikrein-C1-inhibitor complex, it is
conceivable that coagulation activation during CVVH is
decreased following increased endogenous anticoagulant
activity. Indeed, an anticoagulant effect of thrombin infusion
has been reported in a dog model [16]. In the present study,
the protein C levels were no different at baseline between the
two groups; however, we did not measure the 'activated' pro-
tein C levels.
A contribution of the extrinsic pathway to thrombin generation
on artificial surfaces is unexpected at first sight since tissue
factor is normally not found on the surface of cells in contact
Figure 4
Concentrations of kallikrein–C1 inhibitor and activated factor XII–C1-inhibitor complexes during hemofiltration Concentrations of kallikrein–C1 inhibitor and activated factor XII–C1-inhibitor complexes during hemofiltration. Levels are absolute values in order to 
display the significant (P = 0.02) difference at baseline. Data points are median and interquartile ranges. Closed circles, patients with thrombin gen-
eration (group A); open circles, patients without thrombin generation (group B). P value represents the difference in time course between both 
groups by linear mixed models and during the first three hours of hemofiltration. Factor XIIa, activated factor XII.
Figure 5
Plasmin–antiplasmin complexes, tissue plasminogen activator and plasminogen activator inhibitor type 1 during hemofiltration Plasmin–antiplasmin complexes, tissue plasminogen activator and plasminogen activator inhibitor type 1 during hemofiltration. Data points are 
median and interquartile ranges. Closed circles, patients with thrombin generation (group A); open circles, patients without thrombin generation 
(group B). P value represents the difference in time course between both groups by linear mixed models during the first three hours of hemofiltration. 
PAP, plasmin–antiplasmin complexes; t-PA, tissue plasminogen activator; PAI, plasminogen activator inhibitor type 1.Available online http://ccforum.com/content/10/5/R150
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with blood. Monocytes, however, can express tissue factor
under certain pathophysiologic conditions, mostly associated
with increased endotoxin and/or cytokine levels [17]. Based
on the measurements of circulating FVIIa, soluble tissue factor
and TFPI, we did not find signs of activation of coagulation via
the extrinsic pathway. Our findings are in contrast with another
study that concluded activation of tissue factor/FVIIa-medi-
ated coagulation took place in critically ill patients treated with
CVVH [4]. This conclusion was based on increased levels of
thrombin–antithrombin complexes and FVIIa and on
decreased levels of TFPI during CVVH. The change in circulat-
ing FVIIa and TFPI levels, however, was relative to values just
after the start of CVVH with concurrent administration of
heparin. No change in FVIIa and TFPI levels was found when
they were compared with pre-CVVH values. The observed
changes in TFPI and FVIIa in that study may represent the
effects of heparin, rather than activation of the tissue factor/
FVIIa-mediated pathway of coagulation, because the concen-
tration of TFPI increases after administration of heparin [18],
and because high TFPI levels may bind FVIIa. In our study
CVVH was performed without administration of heparin, and
no changes in markers of tissue factor/FVIIa-mediated coagu-
lation were observed.
What is the mechanism of increased thrombin generation in
the absence of detectable activation of the extrinsic coagula-
tion system and intrinsic coagulation system? One explanation
could be a lack of sensitivity of the systemic markers such as
soluble tissue factor, FVIIa and TFPI. The total volume of blood
in the extracorporeal circuit is only approximately 300 ml. The
absolute amount of thrombin formation may therefore be too
low to lead to detectable increases in plasma levels of precur-
sor proteins, such as soluble tissue factor or FVIIa. In that
case, different study designs are needed to show the patho-
physiologic mechanism underlying coagulation during CVVH
(for example, studies analyzing tissue factor expression on
monocytes in prefilter and postfilter samples, or studies
directly analyzing the clot formed in the hemofilter).
Alternatively, an increase in systemic coagulation markers
could be prevented by the removal of markers across the filter
membrane into the ultrafiltrate or secondary to adsorption to
the membrane. The high molecular weight (≥ 35 kDa) and
polarity of coagulation factors, however, should significantly
prevent marker removal during hemofiltration [19]. In our pre-
vious in vitro hemofiltration study using the same cellulose tria-
cetate membrane as in the present study, we found only
minimal filtration of IL-6 (molecular weight, 23–30 kDa) and
the calculated sieving coefficient was approximately 0.1 in the
predilution mode [20]. In general, the process of adsorption to
the membrane is rapidly saturated, but we cannot rule out
some adsorption to the membrane during the first hour of
CVVH.
Finally, it is also conceivable that alternative pathways of
thrombin generation are responsible for filter clotting, includ-
ing the direct activation of factor X, either on the surface of
activated platelets or by the integrin receptor MAC-1 on leuko-
cytes [3].
Low levels of natural anticoagulants have been suggested to
contribute to early filter clotting. In the randomized CRRT
study by Kutsogiannis and colleagues [21], comparing
regional citrate anticoagulation with heparin anticoagulation,
decreasing antithrombin levels were an independent predictor
of an increased risk of filter failure. In the retrospective study
by du Cheyron and colleagues [22] in sepsis patients requir-
ing CRRT and with acquired antithrombin deficiency, antico-
agulation with unfractionated heparin plus antithrombin
supplementation prevented premature filter clotting. In our
own experience, treatment with recombinant human activated
protein C obviated additional anticoagulation during CVVH in
patients with severe sepsis [23]. In the present study, how-
ever, baseline levels of antithrombin and protein C were not
extremely low and no significant difference between patients
with and without early thrombin generation was found.
Another natural defense mechanism against activated coagu-
lation is the fibrinolytic system, and a disturbance of the normal
balance between fibrinolysis and antifibrinolysis might play a
role in thrombosis of the CVVH circuit. In our study the differ-
ence in PAP complex, t-PA and plasminogen activator inhibitor
type 1 levels before and during CVVH were not statistically
significant in patients with and without thrombin generation,
but our study is limited by the small number of patients.
At baseline, the platelet count was significantly lower and the
prothrombin time and activated partial thromboplastin time
were significantly longer in those patients without subsequent
coagulation activation. The association of a low platelet count
with a decreased risk of filter clotting confirms our finding in
earlier studies [24]. The association also confirms the findings
of Holt and colleagues, who showed an association between
the starting activated partial thromboplastin time and the time
to circuit clotting [25].
Conclusion
We conclude that activation of coagulation can be detected in
a minority of intensive care patients treated with CVVH without
anticoagulation. Systemic concentrations of markers of the tis-
sue factor/FVIIa system and the contact system did not
change during CVVH. We suggest that different studies inves-
tigating the activation of coagulation directly at the site of the
filter are needed to elucidate the mechanism of clot formation
during CVVH.
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Key messages
￿  Early increase in thrombin generation can be detected 
in a minority of intensive care patients treated with 
CVVH without anticoagulation.
￿  In patients without early coagulation activation during 
CVVH, the baseline levels of the activated partial throm-
boplastin time, prothrombin time, FXIIa–C1-inhibitor 
complex and kallikrein–C1-inhibitor complex were more 
increased, and the platelet count decreased, in compar-
ison with CVVH patients with early coagulation activa-
tion.
￿  Systemic concentrations of markers of the tissue factor/
FVIIa system and the contact system did not change 
during CVVH.
￿  Early coagulation during CVVH may be related to lower 
baseline levels of markers of contact activation.